Alzheimer’s Disease (AD) is a progressive, neurodegenerative disorder of the brain that is currently estimated to affect 9.8 million people in Europe alone (2019). There are currently no cures which slow down or stop the progress of this disorder. As for the treatment of AD, there are several approved drugs that are actively marketed today. However, these drugs are limited in their efficacy and duration of action and only help to alleviate the symptoms of the disease. It is predicted that, as the population ages, the incidence of AD will significantly increase over the next decades.
Market for Alzheimer's Disease
CHF 10 billion
annual costs in Switzerland
estimated annual costs of EUR 40 billion in DACH region
patients in Switzerland
1’700’000 patients in DACH region
We aim to become a leading provider of non-invasive neuromodulation therapies for early and moderate stage patients suffering from Alzheimer’s disease (AD). The approach consists of electrical brain stimulation sessions which are applied through a wearable headset. With our patented NENI® Matrix platform technology we can test, improve and validate thousands of stimulation protocols targeting glia cells, which play an important role in the progress of AD. We plan to start with clinical trials in 2022 and obtain the CE mark in 2024. Annual costs generated by AD patients in the DACH region (Germany, Austria and Switzerland) are estimated to EUR 40 billion for 2021 and these numbers are increasing due to our ageing society.